satraplatin (JM 216)

structure given in first source

Also Known As:

JM 216; JM-216; JM216; bis-acetatoamminedichlorocyclohexylamine platinum(IV); trans,cis,cis-bis(acetato)amminecyclohexylaminedichloroplatinum(IV); Platinum, bis(acetato-O)amminedichloro(cyclohexanamine)-, (OC-6-43)-

Networked: 93 relevant articles (9 outcomes, 45 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Organometallic Compounds: 64
  - Organoplatinum Compounds
    - satraplatin: 93

Experts

1.	Sternberg, Cora N: 5 articles (01/2012 - 11/2005)
2.	Figg, William D: 3 articles (04/2015 - 09/2013)
3.	Lebwohl, David: 3 articles (01/2005 - 02/2002)
4.	Heffeter, Petra: 2 articles (12/2019 - 08/2015)
5.	Marcus, Leigh: 2 articles (04/2015 - 01/2012)
6.	Sissung, Tristan M: 2 articles (04/2015 - 09/2013)
7.	Warren, Katherine E: 2 articles (04/2015 - 01/2012)
8.	Widemann, Brigitte C: 2 articles (04/2015 - 01/2012)
9.	Vaishampayan, Ulka N: 2 articles (01/2014 - 11/2009)
10.	Gallerani, Elisa: 2 articles (01/2013 - 10/2011)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 11/01/2009 - "The only Phase III trial with satraplatin was conducted in pretreated metastatic castrate-resistant prostate cancer (CRPC), revealing an improvement in progression-free survival but no overall survival benefit. " 09/01/2007 - "Also, the antiproliferative efficacy of satraplatin was tested in vivo in a human prostate cancer model. " 09/01/2007 - "The purpose of this study was to better characterize satraplatin's preclinical antitumor efficacy in a variety of sensitive and resistant human tumor cell lines and in a prostate cancer xenograft model and to evaluate the effect of satraplatin on PSA expression and/or secretion in a prostate cancer cell line. " 09/01/2007 - "In addition, the results suggest that PSA should be further evaluated as a relevant marker of clinical response in patients with prostate cancer treated with satraplatin." 09/01/2013 - "To our knowledge, this is the first prospective study to date in patients with metastatic castration-resistant prostate cancer that describes predictive germline polymorphisms of ERCC1 and XRCC1 for assessing the clinical activity of satraplatin."
2.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/01/2011 - "Gene expression levels of OATP5A1 in small cell lung cancer (SCLC) cell lines were determined by real-time qPCR and chemosensitivity of HEK-293-SLCO5A1-transfected cells to satraplatin in MTT assays. " 09/01/2007 - "When evaluated in the NCI drug-screening panel, satraplatin was most active in leukemia and small cell lung cancer cell lines. " 01/01/2000 - "A group of 24 patients with either non-small-cell lung cancer (NSCLC) stage IIIb/IV or small-cell lung cancer (SCLC), limited disease (LD) or extensive disease (ED), treated with JM216 were studied. " 12/01/1999 - "Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer." 12/01/1999 - "This multicenter phase II trial was performed to determine tumor efficacy and tolerance of the oral platinum drug JM216 in patients with small-cell lung cancer (SCLC). "
3.	Lung Neoplasms (Lung Cancer) 01/01/2007 - "Clinical trials are underway to evaluate satraplatin among patients with different tumour types, including prostate, breast, cervical and lung cancers. " 05/01/1999 - "Our results show that JM216 can potentiate the effects of radiation in human lung cancer cells, and that the mechanism of this effect is probably inhibition of DNA repair by JM216." 01/01/2000 - "These data demonstrate that the combination of JM216 and fractionated radiotherapy is more effective against human lung cancer xenografts than either agent alone, and the in vivo results were supported by those observed using an in vitro system with the same tumor cell line." 11/01/2009 - "Satraplatin has a favorable toxicity profile, and appears to have clinical activity against a variety of malignancies such as breast, prostate and lung cancer. " 01/01/2000 - "Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients."
4.	Ovarian Neoplasms (Ovarian Cancer) 01/01/1998 - "JM216 [bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV)] is an oral platinum complex that is currently in phase II trials in ovarian cancer and lung cancer on a daily-times-5 schedule. " 01/01/2007 - "Furthermore, single-agent satraplatin has demonstrated activity in ovarian cancer and small cell lung cancer similar to that observed with single-agent cisplatin or carboplatin. " 09/01/2001 - "New platinum drugs currently under development that are showing promise in ovarian cancer include oxaliplatin, nedaplatin, satraplatin, BBR3464 and ZD0473. "
5.	Plasmacytoma 08/01/1994 - "Against the murine ADJ/PC6 plasmacytoma, daily x5 administration improved the tolerance, antitumor potency, and therapeutic index of oral JM216, compared to single dose administration, whereas no advantage was found for fractionating cisplatin dosages. " 07/01/2005 - "cisplatin and satraplatin, in repeated doses on the murine ADJ/PC6 plasmacytoma tumor model. " 06/01/1993 - "administration using the cisplatin-sensitive murine ADJ/PC6 plasmacytoma, JM216 showed antitumor selectivity far superior to that observed for either cisplatin, carboplatin, or tetraplatin. " 07/01/2005 - "The murine ADJ/PC6 plasmacytoma and human A2780 ovarian carcinoma tumor model were used to evaluate the in vivo anti-tumor activity of a single dose and also of repeated doses with comparison to the activity of cisplatin and of the platinum(IV) complex satraplatin. "

Related Drugs and Biologics

1.	Platinum
2.	Prednisone (Sone)
3.	Hormones (Hormone)
4.	Cisplatin (Platino)
5.	Oxaliplatin (Eloxatin)
6.	amminedichloro(2- methylpyridine)platinum(II) (ZD0473)
7.	Platinum Compounds (Compounds, Platinum)
8.	BBR 3464 (BBR3464)
9.	PC6 extract (PC6)
10.	nedaplatin

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Radiotherapy
3.	Castration
4.	Therapeutics
5.	Oral Administration